Cargando…
Concurrent opioid and alcohol withdrawal management
Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies. Concurrent use of benzodiazepines and opioid agonists, which are considered first-line agents for management of each withdr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696169/ http://dx.doi.org/10.9740/mhc.2023.12.268 |
_version_ | 1785154514000543744 |
---|---|
author | Colvard, Michelle |
author_facet | Colvard, Michelle |
author_sort | Colvard, Michelle |
collection | PubMed |
description | Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies. Concurrent use of benzodiazepines and opioid agonists, which are considered first-line agents for management of each withdrawal syndrome independently, is controversial and often avoided in clinical practice. Strategies to provide effective, simultaneous medication treatment of alcohol and opioid withdrawal while optimizing patient safety are demonstrated through 3 patient cases. |
format | Online Article Text |
id | pubmed-10696169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association of Psychiatric Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-106961692023-12-06 Concurrent opioid and alcohol withdrawal management Colvard, Michelle Ment Health Clin Psychopharmacology Pearls Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies. Concurrent use of benzodiazepines and opioid agonists, which are considered first-line agents for management of each withdrawal syndrome independently, is controversial and often avoided in clinical practice. Strategies to provide effective, simultaneous medication treatment of alcohol and opioid withdrawal while optimizing patient safety are demonstrated through 3 patient cases. American Association of Psychiatric Pharmacists 2023-12-01 /pmc/articles/PMC10696169/ http://dx.doi.org/10.9740/mhc.2023.12.268 Text en © 2023 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Psychopharmacology Pearls Colvard, Michelle Concurrent opioid and alcohol withdrawal management |
title | Concurrent opioid and alcohol withdrawal management |
title_full | Concurrent opioid and alcohol withdrawal management |
title_fullStr | Concurrent opioid and alcohol withdrawal management |
title_full_unstemmed | Concurrent opioid and alcohol withdrawal management |
title_short | Concurrent opioid and alcohol withdrawal management |
title_sort | concurrent opioid and alcohol withdrawal management |
topic | Psychopharmacology Pearls |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696169/ http://dx.doi.org/10.9740/mhc.2023.12.268 |
work_keys_str_mv | AT colvardmichelle concurrentopioidandalcoholwithdrawalmanagement |